Physician profile
Brynn E Everist
NPI 1093036832
$64,462.21
in general payments reported to CMS, 2019-2025
24 companies · $60K in 2025
The $60K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.28 · 2021: $533 · 2022: $849 · 2023: $952 · 2024: $1,989 · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Travel and Lodging: $8,062 · Food and Beverage: $4,574 · Consulting Fee: $893 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,441.50 |
| Travel and Lodging | $8,061.76 |
| Food and Beverage | $4,573.88 |
| Consulting Fee | $893.18 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60,788.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $941.56 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $857.94 | 2021-2025 | Dupixent |
| Amgen INC. | $314.27 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $285.65 | 2019-2025 | Nucala, Trelegy Ellipta |
| Incyte Corporation | $266.63 | 2023-2025 | Opzelura |
| Blueprint Medicines Corporation | $139.23 | 2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $135.73 | 2022-2025 | |
| Aquestive Therapeutics, INC. | $119.22 | 2025 | |
| Genentech USA, INC. | $105.72 | 2022-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $95.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.16 | 2022-2025 | Takhzyro, Hyqvia |
| Bio Products Laboratory USA, INC. | $47.09 | 2021-2022 | |
| Abbvie INC. | $41.27 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $36.67 | 2025 | Neffy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $34.58 | 2025 | |
| Pfizer INC. | $29.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.69 | 2022 | |
| Optinose US, INC. | $24.09 | 2025 | |
| Grifols USA, LLC | $19.91 | 2025 | Xembify |
| Phathom Pharmaceuticals, INC. | $17.21 | 2025 | Voquezna |
| Chiesi USA, INC. | $14.40 | 2025 | |
| Adma Biomanufacturing LLC | $13.18 | 2025 | |
| Hospira, INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brynn Everist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.